Arginase Inhibition Improves Endothelial Function in Patients With Coronary Artery Disease and Type 2 Diabetes Mellitus | Zendy

Alexey Shemyakin | Zendy; Oskar Kövamees | Zendy; Arnar Rafnsson | Zendy; Felix Böhm | Zendy; Peter Svenarud | Zendy; Magnus Settergren | Zendy; Christian Jung | Zendy; John Pernow | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Arginase Inhibition Improves Endothelial Function in Patients With Coronary Artery Disease and Type 2 Diabetes Mellitus

Author(s) -

Alexey Shemyakin,

Oskar Kövamees,

Arnar Rafnsson,

Felix Böhm,

Peter Svenarud,

Magnus Settergren,

Christian Jung,

John Pernow

Publication year - 2012

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.112.140335

Subject(s) - arginase , medicine , endothelium , diabetes mellitus , endocrinology , nitric oxide , endothelial dysfunction , coronary artery disease , vasodilation , type 2 diabetes mellitus , nitric oxide synthase , arginine , biology , biochemistry , amino acid

Endothelial dysfunction plays an important role in the early development of atherosclerosis and vascular complications in type 2 diabetes mellitus. Increased expression and activity of arginase, metabolizing the nitric oxide substrate l-arginine, may result in reduced production of nitric oxide and thereby endothelial dysfunction. We hypothesized that inhibition of arginase activity improves endothelial function in patients with coronary artery disease (CAD) and type 2 diabetes mellitus.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research